Terms: = Breast cancer AND HER1, YOR227W AND Treatment
165 results:
1. Neratinib for HER2-positive breast cancer with an overlooked option.
Guo L; Shao W; Zhou C; Yang H; Yang L; Cai Q; Wang J; Shi Y; Huang L; Zhang J
Mol Med; 2023 Oct; 29(1):134. PubMed ID: 37803271
[TBL] [Abstract] [Full Text] [Related]
2. Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy.
Chaudhary LN; Jorns JM; Sun Y; Cheng YC; Kamaraju S; Burfeind J; Gonyo MB; Kong AL; Patten C; Yen T; Cortina CS; Carson E; Johnson N; Bergom C; Tsaih SW; Banerjee A; Wang Y; Chervoneva I; Weil E; Chitambar CR; Rui H
Breast Cancer Res Treat; 2023 Oct; 201(3):387-396. PubMed ID: 37460683
[TBL] [Abstract] [Full Text] [Related]
3. Beyond HER2: Targeting the ErbB receptor family in breast cancer.
Drago JZ; Ferraro E; Abuhadra N; Modi S
Cancer Treat Rev; 2022 Sep; 109():102436. PubMed ID: 35870237
[TBL] [Abstract] [Full Text] [Related]
4. Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors.
Lee MX; Wong ALA; Ow S; Sundar R; Tan DSP; Soo RA; Chee CE; Lim JSJ; Yong WP; Lim SE; Goh BC; Wang L; Lee SC
Target Oncol; 2022 Mar; 17(2):141-151. PubMed ID: 35195837
[TBL] [Abstract] [Full Text] [Related]
5. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
6. [Application of neratinib in the treatment of hormone receptor and HER-2 double positive breast cancer].
Wang X; Yuan P
Zhonghua Zhong Liu Za Zhi; 2021 May; 43(5):511-515. PubMed ID: 34034468
[TBL] [Abstract] [Full Text] [Related]
7. Neratinib in the early-stage/extended adjuvant breast cancer patient.
O'Shaughnessy JA; Isaacs C; O'Regan R
Clin Adv Hematol Oncol; 2020 Aug; 18 Suppl 12(8):1-20. PubMed ID: 33843843
[TBL] [Abstract] [Full Text] [Related]
8. Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer.
Yuan Y; Lee JS; Yost SE; Stiller T; Blanchard MS; Padam S; Katheria V; Kim H; Sun C; Tang A; Martinez N; Patel ND; Sedrak MS; Waisman J; Li D; Sanani S; Presant CA; Mortimer J
J Geriatr Oncol; 2021 Jun; 12(5):752-758. PubMed ID: 33663941
[TBL] [Abstract] [Full Text] [Related]
9. The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs.
Sharko AC; Lim CU; McDermott MSJ; Hennes C; Philavong KP; Aiken T; Tatarskiy VV; Roninson IB; Broude EV
Cells; 2021 Jan; 10(1):. PubMed ID: 33445730
[TBL] [Abstract] [Full Text] [Related]
10. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
[TBL] [Abstract] [Full Text] [Related]
11. Integration of Comprehensive Genomic Analysis and Functional Screening of Affected Molecular Pathways to Inform cancer Therapy.
Vasmatzis G; Liu MC; Reganti S; Feathers RW; Smadbeck J; Johnson SH; Schaefer Klein JL; Harris FR; Yang L; Kosari F; Murphy SJ; Borad MJ; Thompson EA; Cheville JC; Anastasiadis PZ
Mayo Clin Proc; 2020 Feb; 95(2):306-318. PubMed ID: 31685261
[TBL] [Abstract] [Full Text] [Related]
12. Transcriptomic and ChIP-sequence interrogation of EGFR signaling in HER2+ breast cancer cells reveals a dynamic chromatin landscape and S100 genes as targets.
Nava M; Dutta P; Zemke NR; Farias-Eisner R; Vadgama JV; Wu Y
BMC Med Genomics; 2019 Feb; 12(1):32. PubMed ID: 30736768
[TBL] [Abstract] [Full Text] [Related]
13. Neratinib in HER2-Positive breast cancer Patients.
Paranjpe R; Basatneh D; Tao G; De Angelis C; Noormohammed S; Ekinci E; Abughosh S; Ghose R; Trivedi MV
Ann Pharmacother; 2019 Jun; 53(6):612-620. PubMed ID: 30607980
[TBL] [Abstract] [Full Text] [Related]
14. Neratinib in Early-Stage breast cancer: A Profile of Its Use in the EU.
Dhillon S
Clin Drug Investig; 2019 Feb; 39(2):221-229. PubMed ID: 30607817
[TBL] [Abstract] [Full Text] [Related]
15. GRB7 dependent proliferation of basal-like, HER-2 positive human breast cancer cell lines is mediated in part by HER-1 signaling.
Luoh SW; Wagoner W; Wang X; Hu Z; Lai X; Chin K; Sears R; Ramsey E
Mol Carcinog; 2019 May; 58(5):699-707. PubMed ID: 30604896
[TBL] [Abstract] [Full Text] [Related]
16. HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women.
Wege AK; Chittka D; Buchholz S; Klinkhammer-Schalke M; Diermeier-Daucher S; Zeman F; Ortmann O; Brockhoff G
Breast Cancer Res; 2018 Nov; 20(1):139. PubMed ID: 30458882
[TBL] [Abstract] [Full Text] [Related]
17. Sialic Acid-Binding Lectin from Bullfrog Eggs Exhibits an Anti-Tumor Effect Against breast cancer Cells Including Triple-Negative Phenotype Cells.
Tatsuta T; Sato S; Sato T; Sugawara S; Suzuki T; Hara A; Hosono M
Molecules; 2018 Oct; 23(10):. PubMed ID: 30347895
[TBL] [Abstract] [Full Text] [Related]
18. Emerging ways to treat breast cancer: will promises be met?
Samadi P; Saki S; Dermani FK; Pourjafar M; Saidijam M
Cell Oncol (Dordr); 2018 Dec; 41(6):605-621. PubMed ID: 30259416
[TBL] [Abstract] [Full Text] [Related]
19. Lapatinib.
Voigtlaender M; Schneider-Merck T; Trepel M
Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
[TBL] [Abstract] [Full Text] [Related]
20. Analysis of HER Family (her1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive breast cancer.
Takada K; Kashiwagi S; Goto W; Asano Y; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2018 Apr; 38(4):2285-2294. PubMed ID: 29599351
[TBL] [Abstract] [Full Text] [Related]
[Next]
